Joint Pain Occurring During Anti-TNF Therapy in Chronic Inflammatory Bowel Disease

Centre Hospitalier Universitaire, Amiens99 enrolled

Overview

IBD (inflammatory bowel disease) are associated with various types of joint manifestations, especially inflammatory. Patients with IBD treated with anti-TNF commonly report joint symptoms, with variable expressions and aetiologies, possibly responsible for impaired quality of life, and possibly leading to discontinuation of an effective and validated treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Inflammatory Bowel Diseases

Interventions

diagnosis of jointOTHER

The diagnosis of joint pain will be established by a rheumatologist and completed: * If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI). * serum assays of the anti-TNF administered, as well as screening for associated antibodies.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males or females over the age of 18 years at the time of inclusion * Patients with IBD (Crohn's disease or ulcerative colitis), diagnosed by a set of compatible clinical (chronic diarrhoea, haematochezia, anoperineal lesions, etc.), laboratory, histological and endoscopic arguments. Patients will be included regardless of the severity of their disease, its clinical course, the type of lesions, and the presence or absence of associated manifestations. * Patients treated with anti-TNF: infliximab or adalimumab. * Informed patients not refusing to participate. * Patients covered by French national health insurance. Exclusion Criteria: * Patients under the age of 18 years at the time of inclusion. * Patients previously treated with anti-TNF, but no longer treated with anti-TNF at the time of inclusion. * Protected majors (under permanent or temporary guardianship).

Locations (1)

CHU Amiens

Amiens, France

Outcomes

Primary Outcomes

Diagnosis of joint pain

presence or absence : The diagnosis of joint pain will be established by a rheumatologist and completed: * If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI). * serum assays of the anti-TNF administered, as well as screening for associated antibodies.

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.